Hepatocellular Carcinoma | Specialty

Patient Profile 2: Patient Progression After Frontline HCC Therapy

April 8th 2024

Drs Saeed and Shroff discuss the next patient profile, focusing on HCC treatment strategies following disease progression after first-line therapy.

Combining Liver-directed and Systemic Therapies in HCC

April 8th 2024

The impact of compounding liver-directed and systemic therapies in HCC management is discussed by Drs Morse and Covey.

Iglesia Spotlights the Current Complexities of Treatment Sequencing in Advanced HCC

April 5th 2024

Michael Iglesia, MD, PhD, discusses the effects of the phase 3 CELESTIAL trial on treatment sequencing strategies in advanced hepatocellular carcinoma.

HCC Treatment Strategy Driven by Real-World Evidence

April 1st 2024

Real-world evidence (RWE) provides critical knowledge for providers constructing a treatment regimen for patients diagnosed with hepatocellular carcinoma.

ASCO GI Updates Provide Window Into Evolving HCC Treatment Paradigm

March 28th 2024

Experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 Gastrointestinal Cancers Symposium.

IMBrave150 Study Overview

March 25th 2024

Dr Gong breaks down the structure and key takeaways from the IMBrave150 study.

Establishing Optimal HCC Treatment Strategy

March 25th 2024

Anwaar Saeed, MD, provides comprehensive insight into the HCC treatment selection process.

HIMALAYA Study in Advanced Stage HCC

March 18th 2024

A comprehensive discussion of the HIMALAYA study, evaluating the STRIDE regimen of durvalumab plus tremelimumab in first-line treatment for advanced HCC.

Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab

March 18th 2024

Medical experts provide insight into managing treatment of advanced HCC through the lens of a patient profile.

IMBrave-050 Study Overview

March 11th 2024

Dr Shroff breaks down the combination of atezolizumab and bevacizumab as outlined by the IMBrave-050 study.

EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies

March 11th 2024

Drs Gong and Covey emphasize the impact of TACE + durvalumab ± bevacizumab combination therapy surrounding HCC treatment strategy.

EMERALD-1 Study: Significance as Presented at ASCO GI 2024

March 4th 2024

Rachna Shroff, MD, MS, FASCO, highlights the prominence of the EMERALD-1 study for patients with HCC.

Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC

March 4th 2024

Michael Morse, MD, establishes his criteria for implementing TACE versus systemic therapy in HCC treatment.

Utilizing Interventional Radiology and Liver-directed Therapies

February 26th 2024

Mechanism of action for liver-directed therapies in HCC are illustrated by Anne Covey, MD, an interventional radiologist.

Hepatocellular Carcinoma (HCC) Disease State Overview

February 26th 2024

Anthony El-Khoueiry, MD, opens the discussion by defining the current prevalence of hepatocellular carcinoma (HCC).

Dr Lencioni on the Results of the EMERALD-1 Trial in Unresectable HCC

January 19th 2024

Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.